Teva Pharmaceuticals (NYSE:TEVA) announced today that it launched generic Erythromycin oral tablets in the U.S. Parsippany, N.J.-based Teva — a U.S. affiliate of Tel Aviv, Israel-based Teva Pharmaceutical Industries — launched the 250 mg- and 500 mg-strength generic Erythromycin tablets, which are a therapeutic equivalent for the reference listed drug Erythromycin from Arbor Pharmaceuticals, according to […]
Teva
Teva Pharmaceuticals unchanged before hours on Q1 earnings beat
Teva Pharmaceuticals (NYSE:TEVA) shares stood firm before hours today on first-quarter earnings that topped the consensus forecast. The Tel Aviv, Israel-based company posted profits of $84 million, or 7¢ per share, on sales of $4 billion for the three months ended March 31, 2021, for a more-than tripled bottom-line despite a sales decline of -8.6%. […]
Teva Pharmaceuticals receives European approval for Spiromax inhalers
Teva Pharmaceuticals announced today that it received European marketing authorization for its Seffalair and BroPair Spiromax inhalers. Seffalair Spiromax and its duplicate BroPair Spiromax (salmeterol xinafoate/ fluticasone propionate, 12.75/100 and 12.75/202 micrograms delivered doses) received approval as a maintenance treatment for asthma in adults and adolescents aged 12 years and older, according to a news […]
8 drug delivery innovations you need to know
The drug delivery space has seen plenty of innovation over the years and there are no signs of that slowing down any time soon. Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means. Among the […]
Teva Pharmaceuticals’ stock sinks 6.5% on Q3 results
Teva (NYSE: TEVA) reported third-quarter results today that matched analysts’ consensus forecast. The company will maintain its guidance for the rest of the year. Teva, which has dual headquarters in Israel and Parsippany, N.J., reported a loss of -$4.3 billion or -$3.97 per share on revenue of $3.9 billion for the quarter ended September 30, […]
Teva wins EU nod for Ajovy migraine prophylactic
Teva (NYSE:TEVA) said yesterday that it won EC Marketing Authorization in the European Union for its Ajovy pre-filled syringe injection meant to serve as a prophylaxis for migraines in adults who experience at least four migraine days per month. The Israel-based company said that Ajovy is a humanized monoclonal antibody that binds to the calcitonin gene-related […]
Ocular continues personnel shakeup with new CMO | Personnel Moves – Sept. 13, 2017
After Ocular Therapeutix‘s (NSDQ:OCUL) founder & CEO, Amar Swahney, stepped down earlier this year, pharma executive Antony Mattessich stepped in to assume the corner office. He signaled some major changes to the company’s business strategy in a call with analysts last month, including an attempt to ‘aggressively seek new partnerships’ and ‘enhance [the company’s] credibility’. As […]
